| Mode of action | Product Candidate or Program | Indication | Discovery | Pre-clinical | Phase 1 | Phase 2 | Phase 3/ Pivotal |
| Cancer metabolism Tumor starvation |
eryaspase /GRASPA® (asparaginase) |
Pancreatic Cancer 2L | |||||
| Triple Negative Breast Cancer 1L | |||||||
| Acute Lymphoblastic Leukemia 2L | |||||||
| Pancreatic cancer 1L | |||||||
| erymethionase (Methionine-γ-Lyase) | Solid tumors | ||||||
| Immune modulation | Immuno-oncology Tolerance induction | TBD* |  |
||||
| Enzyme replacement | Therapeutic Enzymes | Metabolic diseases | |||||
Arrow indicates most advanced study within an indication or program; more detail is provided in subsequent slides
* To be determined by SQZ Biotech